Related Experiment Video
Updated: Feb 1, 2026

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
RLIP depletion suppresses ovarian cancer growth and metastasis
B Madhu Krishna1, Pankaj Garg2, David Horne3
1Department of Medical Oncology and Therapeutic Research, Beckman Research Institute, City of Hope Comprehensive Cancer Center, National Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA.
Highlights:
Key findings of this study with potential clinical relevance include:• RLIP is an attractive therapeutic target with the ability to suppress human OC at multiple stages of development.• Reducing RLIP levels significantly inhibits OC cell growth and enhances apoptosis compared with controls.• RLIP blockade/depletion may serve as a broad-spectrum therapeutic strategy that remains effective regardless of common pathway differences among OC subtypes.• This is the first evidence from integrated in vitro and in vivo studies demonstrating the strong therapeutic promise of RLIP-targeting agents for treating metastatic OC.
Insights
Reducing RLIP levels inhibits ovarian cancer (OC) cell growth and enhances apoptosis. Targeting RLIP offers a promising broad-spectrum therapeutic strategy for metastatic OC, supported by in vitro and in vivo evidence.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Ovarian cancer (OC) remains a significant health challenge.
- Identifying novel therapeutic targets is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate RLIP as a potential therapeutic target for ovarian cancer.
- To evaluate the efficacy of RLIP inhibition in suppressing OC progression.
Main Methods:
- In vitro studies involving OC cell lines.
- In vivo animal models of metastatic OC.
- Assessment of cell growth, apoptosis, and therapeutic agent efficacy.
Main Results:
- RLIP suppression significantly inhibited OC cell growth.
- Reduced RLIP levels enhanced apoptosis in OC cells.
- RLIP blockade demonstrated efficacy across different OC subtypes.
Conclusions:
- RLIP is a viable therapeutic target for ovarian cancer.
- RLIP-targeting agents show promise for treating metastatic OC.
- This study provides the first integrated evidence for RLIP-based OC therapy.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
MOSFET: Depletion Mode
The primary characteristic of depletion-mode MOSFETs is their ability to conduct current between the drain and source terminals without gate bias. This inherent conductivity...
Ovarian Cycle
Population Growth
Meristems and Plant Growth
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...

